search
Back to results

A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3

Primary Purpose

Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
LOXO-435
Pembrolizumab
Sponsored by
Eli Lilly and Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urinary Bladder Neoplasms focused on measuring Bladder Cancer, Bladder Urothelial Carcinoma, Urinary Bladder Cancer, Urinary Tract Cancer, Renal Pelvis Cancer, Ureter Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Have solid tumor cancer with an FGFR3 pathway alteration on molecular testing in tumor or blood sample that is deemed as actionable. Cohort A1 (Dose Escalation): Presence of an alteration in FGFR3 or its ligands. Cohort A2 (Dose Optimization): Histological diagnosis of urothelial cancer (UC) that is locally advanced or metastatic with a qualifying FGFR3 alteration. Cohorts B1, B2 and B3 (Dose Expansion): Histological diagnosis of urothelial cancer that is locally advanced or metastatic with a prespecified activating FGFR3 alteration. Cohort C (Dose Expansion): Must have histological diagnosis of a non-urothelial solid tumor malignancy that is locally advanced or metastatic with a prespecified activating FGFR3 alteration. Measurability of disease: Cohort A1: Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST v1.1) Cohorts A2, B1, B2, B3, and C1: Measurable disease required as defined by RECIST v1.1 Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country-specific regulations. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Prior Systemic Therapy Criteria: Cohort A1/C1: Participant has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating Investigator; OR the participant is refusing the remaining most appropriate standard of care treatment; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies. Cohort A2/B1/B2/B3: Participants must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies. FGFR inhibitor specific requirements: Cohort A1/A2: Prior FGFR inhibitor treatment is permitted, but not required. Cohort B1: Participants must have been previously treated with a FGFR inhibitor. Cohort B2, B3, C1: Participants must be FGFR inhibitor naïve. Exclusion Criteria: Participants with primary central nervous system (CNS) malignancy. Known or suspected history of uncontrolled CNS metastases. Current evidence of corneal keratopathy or retinal disorder. Have a history and/or current evidence of extensive tissue calcification. Any serious unresolved toxicities from prior therapy. Significant cardiovascular disease. Prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF). Active uncontrolled systemic infection or other clinically significant medical conditions. Participants who are pregnant, lactating, or plan to breastfeed during the study or within 6 months of the last dose of study treatment. Participants who have stopped breastfeeding may be enrolled.

Sites / Locations

  • City of Hope Medical CenterRecruiting
  • University of California Los AngelesRecruiting
  • Advent HealthRecruiting
  • Emory UniversityRecruiting
  • Johns Hopkins Kimmel Cancer CenterRecruiting
  • Massachusetts General HospitalRecruiting
  • Barbara Ann Karmanos Cancer InstituteRecruiting
  • Washington University School of MedicineRecruiting
  • New York UniversityRecruiting
  • Icahn School of Medicine at Mount SinaiRecruiting
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer CenterRecruiting
  • University of North Carolina at Chapel HillRecruiting
  • University of Oklahoma Health Sciences CenterRecruiting
  • University of PennsylvaniaRecruiting
  • UPMC Hillman Cancer CenterRecruiting
  • Carolina Urologic Research CenterRecruiting
  • Sarah Cannon and HCA Research InstituteRecruiting
  • University of Texas Southwestern Medical CenterRecruiting
  • MD Anderson Cancer CenterRecruiting
  • University of UtahRecruiting
  • Kinghorn Cancer CentreRecruiting
  • British Columbia Cancer AgencyRecruiting
  • Centre Leon BerardRecruiting
  • Universitaetsklinikum TuebingenRecruiting
  • Aichi Cancer Center HospitalRecruiting
  • National Cancer Center HospitalRecruiting
  • National Cancer Center Hospital EastRecruiting
  • The Cancer Institute Hospital of JFCRRecruiting
  • Asan Medical CenterRecruiting
  • Seoul National University HospitalRecruiting
  • Severance Hospital, Yonsei University Health SystemRecruiting
  • Samsung Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Phase 1a: Cohort A1 LOXO-435 Monotherapy Dose Escalation

Phase 1a: Cohort A2 LOXO-435 Monotherapy Dose Optimization

Phase 1b: Cohort B1 LOXO-435 Monotherapy Dose Expansion

Phase 1b: Cohort B2 LOXO-435 Monotherapy Dose Expansion

Phase 1b: Cohort B3 LOXO-435 Plus Pembrolizumab

Phase 1b: Cohort C1 LOXO-435 Monotherapy Dose Expansion

Arm Description

LOXO-435 administered orally to participants with FGFR3-altered advanced solid tumors.

LOXO-435 administered orally to participants with FGFR3-altered advanced urothelial carcinoma. (Cohort to be implemented as needed, based on Sponsor's discretion.)

LOXO-435 administered orally to participants with FGFR3-altered advanced urothelial carcinoma who were previously treated with an FGFR inhibitor.

LOXO-435 administered orally to participants with FGFR3-altered advanced urothelial carcinoma who have not received a prior FGFR inhibitor.

LOXO-435 administered orally in combination with pembrolizumab administered intravenously (IV) to participants with FGFR3-altered advanced urothelial carcinoma who have not received a prior FGFR inhibitor.

LOXO-435 administered orally to participants with advanced solid tumors who have not received a prior FGFR inhibitor.

Outcomes

Primary Outcome Measures

Phase 1a: To determine the recommended phase 2 dose (RP2D)/optimal dose of LOXO-435: Safety, number of participants with dose-limiting toxicities (DLTs)
Number of participants with DLTs
Phase 1b: To evaluate the preliminary antitumor activity of LOXO-435: Overall response rate (ORR)
ORR per investigator assessed RECIST v1.1

Secondary Outcome Measures

To assess the pharmacokinetics (PK) of LOXO-435: Area under the concentration versus time curve (AUC)
PK of LOXO-435: AUC
To assess the PK of LOXO-435: Minimum plasma concentration (Cmin)
PK of LOXO-435: Cmin
To evaluate the preliminary antitumor activity of LOXO-435: Duration of response (DoR)
DOR per investigator assessed RECIST 1.1
To evaluate the preliminary antitumor activity of LOXO-435: Time to response (TTR)
TTR
To evaluate the preliminary antitumor activity of LOXO-435: Progression-free survival (PFS)
PFS per investigator assessed RECIST 1.1
To evaluate the preliminary antitumor activity of LOXO-435: Disease control rate (DCR)
DCR per investigator assessed RECIST 1.1
To evaluate the preliminary antitumor activity of LOXO-435: Overall survival (OS)
OS
Change from baseline in bladder-related symptoms, measured by Functional Assessment of Cancer Therapy - Bladder (FACT-Bl) subscale (BlCS)
The BlCS has 12 items with a total score range of 0 to 48, with higher scores representing better bladder-related symptoms. A ≥ 4-point score change from baseline will be considered as clinically meaningful improvement in bladder-related symptoms
Change from baseline in physical function, measured by FACT- Physical Well-being Scale (PWB) subscale
The PWB subscale has 7 items with a total score range of 0-28, with higher scores representing better physical function. A ≥ 3-point score change from baseline for a participant will be considered as clinically meaningful improvement in physical function.

Full Information

First Posted
November 7, 2022
Last Updated
October 11, 2023
Sponsor
Eli Lilly and Company
Collaborators
Loxo Oncology, Inc., Merck Sharp & Dohme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05614739
Brief Title
A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
Official Title
An Open-Label, Multicenter Study of LOXO-435 (LY3866288) In Advanced Solid Tumor Malignancies With FGFR3 Alterations
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 12, 2023 (Actual)
Primary Completion Date
June 2025 (Anticipated)
Study Completion Date
June 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eli Lilly and Company
Collaborators
Loxo Oncology, Inc., Merck Sharp & Dohme LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.
Detailed Description
This is an open-label, multi-center, phase 1a/b study in participants with FGFR3-altered advanced solid tumors, including metastatic urothelial cancer (UC). The study will be conducted in 2 phases: Dose escalation and dose optimization (1a) and dose expansion (1b). Phase 1a will include up to 2 cohorts to assess safety, tolerability, and pharmacokinetics of LOXO-435 to determine the recommended phase 2 dose (RP2D) (or optimal dose). Phase 1b will include 4 dose expansion cohorts of participants with prespecified activating FGFR3 alterations to evaluate the efficacy and safety of LOXO-435 at the RP2D. Cohort B will enroll pts with metastatic UC and includes three cohorts to evaluate LOXO-435 as monotherapy (B1, B2) and in combination with pembrolizumab (B3). Cohort C will enroll pts with non-UC advanced solid tumors and includes a cohort to evaluate LOXO-435 as monotherapy (C1).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
Keywords
Bladder Cancer, Bladder Urothelial Carcinoma, Urinary Bladder Cancer, Urinary Tract Cancer, Renal Pelvis Cancer, Ureter Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
180 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Phase 1a: Cohort A1 LOXO-435 Monotherapy Dose Escalation
Arm Type
Experimental
Arm Description
LOXO-435 administered orally to participants with FGFR3-altered advanced solid tumors.
Arm Title
Phase 1a: Cohort A2 LOXO-435 Monotherapy Dose Optimization
Arm Type
Experimental
Arm Description
LOXO-435 administered orally to participants with FGFR3-altered advanced urothelial carcinoma. (Cohort to be implemented as needed, based on Sponsor's discretion.)
Arm Title
Phase 1b: Cohort B1 LOXO-435 Monotherapy Dose Expansion
Arm Type
Experimental
Arm Description
LOXO-435 administered orally to participants with FGFR3-altered advanced urothelial carcinoma who were previously treated with an FGFR inhibitor.
Arm Title
Phase 1b: Cohort B2 LOXO-435 Monotherapy Dose Expansion
Arm Type
Experimental
Arm Description
LOXO-435 administered orally to participants with FGFR3-altered advanced urothelial carcinoma who have not received a prior FGFR inhibitor.
Arm Title
Phase 1b: Cohort B3 LOXO-435 Plus Pembrolizumab
Arm Type
Experimental
Arm Description
LOXO-435 administered orally in combination with pembrolizumab administered intravenously (IV) to participants with FGFR3-altered advanced urothelial carcinoma who have not received a prior FGFR inhibitor.
Arm Title
Phase 1b: Cohort C1 LOXO-435 Monotherapy Dose Expansion
Arm Type
Experimental
Arm Description
LOXO-435 administered orally to participants with advanced solid tumors who have not received a prior FGFR inhibitor.
Intervention Type
Drug
Intervention Name(s)
LOXO-435
Other Intervention Name(s)
LY3866288
Intervention Description
Oral
Intervention Type
Drug
Intervention Name(s)
Pembrolizumab
Intervention Description
IV
Primary Outcome Measure Information:
Title
Phase 1a: To determine the recommended phase 2 dose (RP2D)/optimal dose of LOXO-435: Safety, number of participants with dose-limiting toxicities (DLTs)
Description
Number of participants with DLTs
Time Frame
Minimum of the first 21-day cycle of LOXO-435 treatment
Title
Phase 1b: To evaluate the preliminary antitumor activity of LOXO-435: Overall response rate (ORR)
Description
ORR per investigator assessed RECIST v1.1
Time Frame
Up to approximately 30 months or 2.5 years
Secondary Outcome Measure Information:
Title
To assess the pharmacokinetics (PK) of LOXO-435: Area under the concentration versus time curve (AUC)
Description
PK of LOXO-435: AUC
Time Frame
Up to 2 months
Title
To assess the PK of LOXO-435: Minimum plasma concentration (Cmin)
Description
PK of LOXO-435: Cmin
Time Frame
Up to 2 months
Title
To evaluate the preliminary antitumor activity of LOXO-435: Duration of response (DoR)
Description
DOR per investigator assessed RECIST 1.1
Time Frame
Up to approximately 30 months or 2.5 years
Title
To evaluate the preliminary antitumor activity of LOXO-435: Time to response (TTR)
Description
TTR
Time Frame
Up to approximately 30 months or 2.5 years
Title
To evaluate the preliminary antitumor activity of LOXO-435: Progression-free survival (PFS)
Description
PFS per investigator assessed RECIST 1.1
Time Frame
Up to approximately 30 months or 2.5 years
Title
To evaluate the preliminary antitumor activity of LOXO-435: Disease control rate (DCR)
Description
DCR per investigator assessed RECIST 1.1
Time Frame
Up to approximately 30 months or 2.5 years
Title
To evaluate the preliminary antitumor activity of LOXO-435: Overall survival (OS)
Description
OS
Time Frame
Up to approximately 30 months or 2.5 years
Title
Change from baseline in bladder-related symptoms, measured by Functional Assessment of Cancer Therapy - Bladder (FACT-Bl) subscale (BlCS)
Description
The BlCS has 12 items with a total score range of 0 to 48, with higher scores representing better bladder-related symptoms. A ≥ 4-point score change from baseline will be considered as clinically meaningful improvement in bladder-related symptoms
Time Frame
Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 3 Day 1 (28 day cycles)
Title
Change from baseline in physical function, measured by FACT- Physical Well-being Scale (PWB) subscale
Description
The PWB subscale has 7 items with a total score range of 0-28, with higher scores representing better physical function. A ≥ 3-point score change from baseline for a participant will be considered as clinically meaningful improvement in physical function.
Time Frame
Up to approximately 30 months or 2.5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Have solid tumor cancer with an FGFR3 pathway alteration on molecular testing in tumor or blood sample that is deemed as actionable. Cohort A1 (Dose Escalation): Presence of an alteration in FGFR3 or its ligands. Cohort A2 (Dose Optimization): Histological diagnosis of urothelial cancer (UC) that is locally advanced or metastatic with a qualifying FGFR3 alteration. Cohorts B1, B2 and B3 (Dose Expansion): Histological diagnosis of urothelial cancer that is locally advanced or metastatic with a prespecified activating FGFR3 alteration. Cohort C (Dose Expansion): Must have histological diagnosis of a non-urothelial solid tumor malignancy that is locally advanced or metastatic with a prespecified activating FGFR3 alteration. Measurability of disease: Cohort A1: Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST v1.1) Cohorts A2, B1, B2, B3, and C1: Measurable disease required as defined by RECIST v1.1 Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country-specific regulations. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Prior Systemic Therapy Criteria: Cohort A1/C1: Participant has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating Investigator; OR the participant is refusing the remaining most appropriate standard of care treatment; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies. Cohort A2/B1/B2/B3: Participants must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies. FGFR inhibitor specific requirements: Cohort A1/A2: Prior FGFR inhibitor treatment is permitted, but not required. Cohort B1: Participants must have been previously treated with a FGFR inhibitor. Cohort B2, B3, C1: Participants must be FGFR inhibitor naïve. Exclusion Criteria: Participants with primary central nervous system (CNS) malignancy. Known or suspected history of uncontrolled CNS metastases. Current evidence of corneal keratopathy or retinal disorder. Have a history and/or current evidence of extensive tissue calcification. Any serious unresolved toxicities from prior therapy. Significant cardiovascular disease. Prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF). Active uncontrolled systemic infection or other clinically significant medical conditions. Participants who are pregnant, lactating, or plan to breastfeed during the study or within 6 months of the last dose of study treatment. Participants who have stopped breastfeeding may be enrolled.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Patient Advocacy
Phone
855-569-6305
Email
clinicaltrials@loxooncology.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ryan Widau, PhD
Organizational Affiliation
Loxo Oncology, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
City of Hope Medical Center
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
University of California Los Angeles
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Advent Health
City
Orlando
State/Province
Florida
ZIP/Postal Code
32804
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Johns Hopkins Kimmel Cancer Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21231-2410
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Barbara Ann Karmanos Cancer Institute
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
New York University
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
University of North Carolina at Chapel Hill
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599-7305
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
University of Oklahoma Health Sciences Center
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
UPMC Hillman Cancer Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Carolina Urologic Research Center
City
Myrtle Beach
State/Province
South Carolina
ZIP/Postal Code
29572
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Sarah Cannon and HCA Research Institute
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
University of Texas Southwestern Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030-4009
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84132
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Kinghorn Cancer Centre
City
Darlinghurst
ZIP/Postal Code
NSW 2010
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
British Columbia Cancer Agency
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 1J3
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Centre Leon Berard
City
Lyon
ZIP/Postal Code
69008
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Universitaetsklinikum Tuebingen
City
Tuebingen
ZIP/Postal Code
72076
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Aichi Cancer Center Hospital
City
Nagoya
State/Province
Aichi
ZIP/Postal Code
464-8681
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
National Cancer Center Hospital
City
Chuo Ku
State/Province
Tokyo
ZIP/Postal Code
104-0045
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
National Cancer Center Hospital East
City
Chiba
ZIP/Postal Code
277-8577
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
The Cancer Institute Hospital of JFCR
City
Tokyo
ZIP/Postal Code
135-8550
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Asan Medical Center
City
Songpa-gu
State/Province
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Severance Hospital, Yonsei University Health System
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305
Facility Name
Samsung Medical Center
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
Phone
855-569-6305

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://trials.lilly.com/en-US/trial/367675
Description
A Study of LOXO-435 in Patients With Cancer With a Change in a Gene Called FGFR3

Learn more about this trial

A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3

We'll reach out to this number within 24 hrs